SCHEMBL24310773

SCHEMBL24310773

CB(O)c1cccnc1OC(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC13A5 Q86YT5 1/20 0.39
ALOX5AP P20292 2/20 0.36
FEN1 P39748 2/20 0.36
FFAR4 Q5NUL3 4/20 0.36
LRRK2 Q5S007 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.35
HCRTR1 O43613 3/20 0.34
HCRTR2 O43614 3/20 0.34
LIPG Q9Y5X9 1/20 0.34
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
MKNK2 Q9HBH9 1/20 0.33
TYK2 P29597 1/20 0.33
GRM5 P41594 1/20 0.33
GPBAR1 Q8TDU6 1/20 0.32
BRD4 O60885 1/20 0.32
BRPF1 P55201 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1890438 0.89 SLC13A5 (0.41) SLC13A5ALOX5APFEN1FFAR4LRRK2
SCHEMBL11989067 0.80 APLNR (0.42) SLC13A5GRM5KDM4E
SCHEMBL12098002 0.76 SLC13A5 (0.39) SLC13A5ALOX5APFEN1FFAR4LRRK2
SCHEMBL28782451 0.75 ALOX5AP (0.39) SLC13A5ALOX5APFEN1FFAR4LRRK2
SCHEMBL18883107 0.74 TRPV4 (0.49) TYK2KDM4EMAPT
SCHEMBL29900389 0.74 TRPV4 (0.49) TYK2KDM4EMAPT
SCHEMBL29497424 0.72 LRRK2 (0.45) SLC13A5ALOX5APFEN1FFAR4LRRK2
SCHEMBL2614923 0.72 LRRK2 (0.45) SLC13A5ALOX5APFEN1FFAR4LRRK2
SCHEMBL29057683 0.71 TRPV4 (0.36)
SCHEMBL759910 0.71 LRRK2 (0.40) SLC13A5ALOX5APFEN1FFAR4LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 US disclosed
WO-2022076627-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B SLC13A5 1352/4885ALOX5AP 2538/4885FEN1 3816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.